EET-Based Therapeutics Mitigate Sorafenib-Associated Glomerular Cell Damage
Biomolecules · 16.09.2025 · 15 (9) · 1324
DOI: 10.3390/biom15091324 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, online erschienen am 16.09.2025. Verfasst von Abhishek Mishra und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA. Hauptthemen laut MEDLINE: Sorafenib, Podocytes, Mesangial Cells. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, Arkansas Research Alliance, Arkansas Biosciences Institute.
Abstract (Originalsprache)
Background
This study investigates how sorafenib induces toxicity in glomerular cells and examines the protective role of 8,9-epoxyeicosatrienoic acid (8,9-EET) analogs in reducing this kidney damage.
Methods
Human renal mesangial cells (HRMCs) and podocytes were treated with no treatment, sorafenib alone, or sorafenib combined with 8,9-EET analogs. Cell viability and apoptosis were measured in both cell types.
Results
Sorafenib (1–10 µM) lowered cell viability and increased caspase 3/7 activity in a dose-dependent way in HRMCs and podocytes. Five of twenty 8,9-EET analogs significantly enhanced cell survival and decreased apoptosis. RNA sequencing showed that sorafenib altered 1244 genes, including those involved in cell cycle and the Raf/MEK/ERK pathway. The 8,9-EET analog MDB-52a raised ANGPTL4 levels, linked to metabolism and vascular health, and reduced ACTA2, which could activate protective pathways. Nephroseq data correlated these gene changes with glomerulosclerosis.
Conclusions
MDB-52 appears to counteract gene disruptions and protect against sorafenib-induced kidney damage. Overall, 8,9-EET analogs targeting glomerular cells could be potential therapeutic agents to lessen sorafenib-related nephrotoxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
- Department of Pharmacy, Section for Pharmaceutical Chemistry, University of Oslo, 0316 Oslo, Norway.
- Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
ORCID-Profile: Abhishek Mishra, Tsigereda Weldemichael, Darin E Jones, Anders Vik, John D Imig
Förderung
- NIDDK NIH HHS
- Arkansas Research Alliance
- Arkansas Biosciences Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Mishra, A., de Bourg, M., Mohamed, R. S., Hye Khan, M. A., Weldemichael, T., Johann, D. J., Goorani, S., Bommagani, S., Jones, D. E., Vik, A., & Imig, J. D. (2025). EET-Based Therapeutics Mitigate Sorafenib-Associated Glomerular Cell Damage. Biomolecules, 15(9), 1324. https://doi.org/10.3390/biom15091324
Vancouver
Mishra A, de Bourg M, Mohamed RS, Hye Khan MA, Weldemichael T, Johann DJ, et al. EET-Based Therapeutics Mitigate Sorafenib-Associated Glomerular Cell Damage. Biomolecules. 2025;15(9):1324. doi:10.3390/biom15091324
BibTeX
@article{Mishra2025,
author = {Mishra, Abhishek and de Bourg, Marcus and Mohamed, Rawand S and Hye Khan, Md Abdul and Weldemichael, Tsigereda and Johann, Donald J and Goorani, Samaneh and Bommagani, Shobanbabu and Jones, Darin E and Vik, Anders and Imig, John D},
title = {EET-Based Therapeutics Mitigate Sorafenib-Associated Glomerular Cell Damage},
journal = {Biomolecules},
year = {2025},
volume = {15},
number = {9},
pages = {1324},
doi = {10.3390/biom15091324}
}
EUVIMED